Ambisome Market Size, Share and Trends Analysis Report, By Application (Vaginitis, Candida Infection, Leishmaniasis, Kala-Azar, Cryptococcal Infection, Aspergillus Infection, and Others) Forecast (2022-2028)

The global ambisome market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ambisome is a polyene class of drug and it is a subgroup of macrolide antibiotics. Ambisome works by interfering cell membrane of fungus which is used in the treatment of critical fungal infections, leishmaniasis, and others. The global ambisome market is growing due to the rising prevalence of fungal and hospital-acquired infections as well as the increasing mucormycosis infections. The large investment in research and development activities by the key manufacturers for the development of the drugs to treat these diseases as well as improved healthcare infrastructure in the emerging economic countries to adopt new treatments methods are also boosting the market growth. Additionally, the rise in consumption of antifungal drugs as well as the approval of generic drugs is also driving the growth of the global ambisome market.

The market player is contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and launches, to stay competitive in the market. For instance-

• In February 2022, Sun Pharmaceutical Industries Ltd. announced the launch of its generic version of Astellas Pharma Inc. and Gilead Sciences, Inc. product AmBisome, an amphotericin B liposome injection.
• In June 2021, Celon Pharma S.A. launched Amphotericin B Emulsion for mucormycosis commonly known as a black fungus.
• In June 2021, SP Accure Labs Pvt. Ltd. launched the alternative drug Amphotericin-B-Emulation for the effective treatment of mucormycosis.
• In May 2021, Strides Pharma Science Ltd. and TLC Pharmaceutical Standards Ltd. partnered together for the launch of Amphotericin B Liposome in 50 mg injection after getting approval from the Central Drugs Standard Control Organization (CDSCO) of India.

Market Coverage

• The market number available for – 2022-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Bristol-Myers Squibb Co., Jina Pharma, Eli Lilly and Co., Astellas Pharma Inc., and Leadiant Biosciences, Inc.,among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ambisome Market Report by Segment

By Application

• Vaginitis
• Candida Infection
• Leishmaniasis
• Kala-Azar
• Cryptococcal Infection
• Aspergillus Infection
• Others

Global Ambisome Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa